Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report

Overview

Journal Stem Cell Reports

Publisher Cell Press

Specialty Cell Biology

Date 2018 Nov 15

PMID 30428384

Citations 8

Authors

Jeremy Sugarman

Roger A Barker

Ian Kerridge

Tamra Lysaght

Graziella Pellegrini

Douglas Sipp

Claire Tanner

Affiliations

Soon will be listed here.

Abstract

Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.

Citing Articles

US state laws on medical freedom and investigational stem cell procedures: a call to focus on state-based legislation.

Matthews K, Lowe S, Master Z Cytotherapy. 2024; 26(4):404-409.

PMID: 38310500 PMC: 11010147. DOI: 10.1016/j.jcyt.2024.01.002.

Unproven cell interventions in Poland and the exploitation of European Union law on advanced therapy medicinal products.

Dulak J, Pecyna M Stem Cell Reports. 2023; 18(8):1610-1620.

PMID: 37390824 PMC: 10444563. DOI: 10.1016/j.stemcr.2023.05.017.

An Infodemic of Misinformation on Stem Cell Therapy Among the Population of Saudi Arabia: A Cross-Sectional Study.

Aboalola D, Badraiq H, Alsiary R, Zakri S, Aboulola N, Haneef L Front Med (Lausanne). 2022; 9:789695.

PMID: 35308548 PMC: 8924302. DOI: 10.3389/fmed.2022.789695.

ISSCR's Guidelines for Stem Cell Research and Clinical Translation: Supporting development of safe and efficacious stem cell-based interventions.

Turner L Stem Cell Reports. 2021; 16(6):1394-1397.

PMID: 34048693 PMC: 8190662. DOI: 10.1016/j.stemcr.2021.05.011.

Regenerative Medicine of Epithelia: Lessons From the Past and Future Goals.

Maurizi E, Adamo D, Magrelli F, Galaverni G, Attico E, Merra A Front Bioeng Biotechnol. 2021; 9:652214.

PMID: 33842447 PMC: 8026866. DOI: 10.3389/fbioe.2021.652214.

References

Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S . Marketing of unproven stem cell-based interventions: A call to action. Sci Transl Med. 2017; 9(397). DOI: 10.1126/scitranslmed.aag0426. View

Turner L . ClinicalTrials.gov, stem cells and 'pay-to-participate' clinical studies. Regen Med. 2017; 12(6):705-719. DOI: 10.2217/rme-2017-0015. View

Kuriyan A, Albini T, Townsend J, Rodriguez M, Pandya H, Leonard 2nd R . Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD. N Engl J Med. 2017; 376(11):1047-1053. PMC: 5551890. DOI: 10.1056/NEJMoa1609583. View

Barker R, Carpenter M, Forbes S, Goldman S, Jamieson C, Murry C . The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?. Stem Cell Reports. 2018; 10(5):1429-1431. PMC: 5995446. DOI: 10.1016/j.stemcr.2018.04.010. View

Berkowitz A, Miller M, Mir S, Cagney D, Chavakula V, Guleria I . Glioproliferative Lesion of the Spinal Cord as a Complication of "Stem-Cell Tourism". N Engl J Med. 2016; 375(2):196-8. DOI: 10.1056/NEJMc1600188. View

Sipp D . Conditional approval: Japan lowers the bar for regenerative medicine products. Cell Stem Cell. 2015; 16(4):353-6. DOI: 10.1016/j.stem.2015.03.013. View

Horowitz M . The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008; 42 Suppl 1:S1-S2. DOI: 10.1038/bmt.2008.101. View

Tanner C, Petersen A, Munsie M . 'No one here's helping me, what do you do?': addressing patient need for support and advice about stem cell treatments. Regen Med. 2017; 12(7):791-801. DOI: 10.2217/rme-2017-0056. View

Bianco P, Cao X, Frenette P, Mao J, Robey P, Simmons P . The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med. 2013; 19(1):35-42. PMC: 3998103. DOI: 10.1038/nm.3028. View

10.

Kimmelman J, London A . The structure of clinical translation: efficiency, information, and ethics. Hastings Cent Rep. 2015; 45(2):27-39. DOI: 10.1002/hast.433. View

11.

Munsie M, Lysaght T, Hendl T, Tan H, Kerridge I, Stewart C . Open for business: a comparative study of websites selling autologous stem cells in Australia and Japan. Regen Med. 2017; 12(7):777-790. DOI: 10.2217/rme-2017-0070. View

12.

Turner L, Knoepfler P . Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. Cell Stem Cell. 2016; 19(2):154-157. DOI: 10.1016/j.stem.2016.06.007. View

13.

Petersen A, Tanner C, Munsie M . Between hope and evidence: how community advisors demarcate the boundary between legitimate and illegitimate stem cell treatments. Health (London). 2014; 19(2):188-206. DOI: 10.1177/1363459314555240. View

14.

Lee T, Lysaght T . Conditional Approvals for Autologous Stem Cell-Based Interventions: . Perspect Biol Med. 2018; 61(1):59-75. DOI: 10.1353/pbm.2018.0027. View

15.

Lysaght T, Munsie M, Castricum A, Hui J, Okada K, Sato Y . A roundtable on responsible innovation with autologous stem cells in Australia, Japan and Singapore. Cytotherapy. 2018; 20(9):1103-1109. DOI: 10.1016/j.jcyt.2018.06.004. View

16.

Lysaght T, Kerridge I, Sipp D, Porter G, Capps B . Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations. J Bioeth Inq. 2017; 14(2):261-273. DOI: 10.1007/s11673-017-9776-y. View

17.

Lau D, Ogbogu U, Taylor B, Stafinski T, Menon D, Caulfield T . Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell. 2008; 3(6):591-4. DOI: 10.1016/j.stem.2008.11.001. View